146 related articles for article (PubMed ID: 21081599)
1. Open letter to prime minister David Cameron and health secretary Andrew Lansley.
Nicholl DJ; Hilton-Jones D; Palace J; Richmond S; Finlayson S; Winer J; Weir A; Maddison P; Fletcher N; Sussman J; Silver N; Nixon J; Kullmann D; Embleton N; Beeson D; Farrugia ME; Hill M; McDermott C; Llewelyn G; Leonard J; Morris M
BMJ; 2010 Nov; 341():c6466. PubMed ID: 21081599
[No Abstract] [Full Text] [Related]
2. Open letter to UK Prime Minister David Cameron and Health Secretary Andrew Lansley on safety of medicines.
Archibald K; Coleman R; Foster C
Lancet; 2011 Jun; 377(9781):1915. PubMed ID: 21641471
[No Abstract] [Full Text] [Related]
3. The Orphan Drug Act Revisited.
Thomas S; Caplan A
JAMA; 2019 Mar; 321(9):833-834. PubMed ID: 30768155
[No Abstract] [Full Text] [Related]
4. Rare diseases and effective treatments: are we delivering?
Luzzatto L; Hollak CE; Cox TM; Schieppati A; Licht C; Kääriäinen H; Merlini G; Schaefer F; Simoens S; Pani L; Garattini S; Remuzzi G
Lancet; 2015 Feb; 385(9970):750-2. PubMed ID: 25752159
[No Abstract] [Full Text] [Related]
5. Adoption agents.
Wapner J
Sci Am; 2010 Jun; 302(6):19-20. PubMed ID: 20521471
[No Abstract] [Full Text] [Related]
6. The orphan drug backlash.
Maeder T
Sci Am; 2003 May; 288(5):80-7. PubMed ID: 12701333
[No Abstract] [Full Text] [Related]
7. Outrageous prices of orphan drugs: a call for collaboration.
Luzzatto L; Hyry HI; Schieppati A; Costa E; Simoens S; Schaefer F; Roos JCP; Merlini G; Kääriäinen H; Garattini S; Hollak CE; Remuzzi G;
Lancet; 2018 Sep; 392(10149):791-794. PubMed ID: 30037734
[No Abstract] [Full Text] [Related]
8. [Orphan drugs--medications for patients with rare diseases].
Thielke D; Thyssen JP; Hansen BJ
Ugeskr Laeger; 2006 Jun; 168(23):2236-8. PubMed ID: 16768975
[TBL] [Abstract][Full Text] [Related]
9. HHS defends expanded 340B drug discounts.
Lee J
Mod Healthc; 2014 Jun; 44(24):9. PubMed ID: 25137989
[No Abstract] [Full Text] [Related]
10. The price you pay.
Drug Ther Bull; 2010 Sep; 48(9):97. PubMed ID: 20810707
[No Abstract] [Full Text] [Related]
11. Does orphan drug legislation really answer the needs of patients?
Haffner ME; Torrent-Farnell J; Maher PD
Lancet; 2008 Jun; 371(9629):2041-4. PubMed ID: 18555916
[No Abstract] [Full Text] [Related]
12. Lucrative niches: how drugs for rare diseases became lifeline for companies.
Anand G
Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531
[No Abstract] [Full Text] [Related]
13. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
Liu BC; He L; He G; He Y
J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
[TBL] [Abstract][Full Text] [Related]
14. Regulators adopt more orphan drugs.
Reardon S
Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293
[No Abstract] [Full Text] [Related]
15. Reforming the Orphan Drug Act for the 21st Century.
Sarpatwari A; Kesselheim AS
N Engl J Med; 2019 Jul; 381(2):106-108. PubMed ID: 31291512
[No Abstract] [Full Text] [Related]
16. Should off-label drug use be off-the-table?
Rivkees SA
J Pediatr Endocrinol Metab; 2007 Feb; 20(2):171-2. PubMed ID: 17396432
[No Abstract] [Full Text] [Related]
17. Policymaking for Orphan Drugs and Its Challenges.
Rhee TG
AMA J Ethics; 2015 Aug; 17(8):776-9. PubMed ID: 26270879
[No Abstract] [Full Text] [Related]
18. Orphan economics: the downside of supplyside pharmacology.
Samson K
Ann Neurol; 2008 Sep; 64(3):A13-6. PubMed ID: 18825669
[No Abstract] [Full Text] [Related]
19. From blockbuster to "nichebuster": how a flawed legislation helped create a new profit model for the drug industry.
Marselis D; Hordijk L
BMJ; 2020 Jul; 370():m2983. PubMed ID: 32727745
[No Abstract] [Full Text] [Related]
20. [Drugs for rare diseases].
Rolfs M; Lindemalm S
Lakartidningen; 2010 Apr 21-27; 107(16):1043. PubMed ID: 20476696
[No Abstract] [Full Text] [Related]
[Next] [New Search]
